 La Jolla Pharmaceutical Company LJPC, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. TTPH, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM to treat serious and life-threatening infections, today announced that they have entered into a definitive merger agreement. Under the terms of the definitive merger agreement, La Jolla would acquire Tetraphase, through a tender offer, for 43.0 million in upfront cash plus potential future cash payments of up to 16.0 million pursuant to contingent value rights CVRs. 